Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. - Wikidata - wikimedia - TriplyDB

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

http://www.wikidata.org/entity/Q38896657

about

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.MiR21 sensitized B-lymphoma cells to ABT-199 via ICOS/ICOSL-mediated interaction of Treg cells with endothelial cells The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines.FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.Development of venetoclax for therapy of lymphoid malignancies.Non-Hodgkin and Hodgkin lymphomas select for overexpression of BCLW.Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies Novel agents in mantle cell lymphoma.Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax.CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.Mixed-species RNAseq analysis of human lymphoma cells adhering to mouse stromal cells identifies a core gene set that is also differentially expressed in the lymph node microenvironment of mantle cell lymphoma and chronic lymphocytic leukemia patien Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.Pathways and mechanisms of venetoclax resistance.Accelerated inflammation and oxidative stress induced by LPS in acute lung injury: Ιnhibition by ST1926.Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA

P2860

Q28075606-6D863351-8FA2-4174-8C5C-5B8227AAE927 Q30395557-B966935E-3FCB-4B2A-A7F5-D5FBF9C940F8 Q33823801-650F0DA2-C45F-4820-94E2-7CF985F64669 Q36163122-F2AA75E7-9B6A-47E0-8079-D481A648B8F0 Q36601134-977E8E94-1990-44A2-BB5B-93BFD0926AAE Q36998291-2A899132-4665-4586-A960-797EE1E4001A Q37404843-6EC5CB92-1121-44B1-B6A0-9A08A3B601D9 Q37702281-172DB62F-EB3F-4A4A-AAEF-66EA306249B8 Q38601661-72D7FDF6-5E5E-4122-8315-5E2044DAE6FC Q38637652-9C44B650-380E-48FF-BE0D-E5A6FC756C60 Q38675161-806CDBF0-E53B-4992-8419-601DDEB734C1 Q38722012-FF7291F7-1D61-4A9D-AA92-16861691B8E8 Q38996888-C814A8FD-AFE2-422B-B928-7697F8E41ED5 Q39290199-840A0CE8-6305-4106-8741-84CEF0460A21 Q39434177-A6EAFF56-2100-4526-9305-FA1500FB299F Q40537266-5C9424DC-70D0-4565-AFBB-7D782BDF972E Q46370948-CA62DF1A-926A-4E87-B835-4AAB42EA46A6 Q47549122-2AE9828B-C655-4951-AAD2-DAA72F9D3A5F Q49959959-852068D4-BFA7-41DA-B40A-06AD66A34875 Q50200754-7EF469F6-AD5C-4ADC-9E14-3ED7676E02E0 Q51160342-F74E028F-BDBA-4B88-8917-795175231D25 Q52641349-5E427EA0-0BFF-48F8-8811-251FC3659476 Q53730905-B9B84D4C-F597-496F-9512-E1501A355F62 Q54998724-67B966FB-ABFC-4311-8114-9AAE0581DF4F Q58580676-DFF1E686-B367-4416-B96A-7C5D686B8800 Q58765200-42C1C558-465E-4F63-9531-CAE7F35E40C9

P2860

Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.

http://www.wikidata.org/entity/Q38896657

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Biological rational for sequen ...... tance in mantle cell lymphoma.

@en

type

label

Biological rational for sequen ...... tance in mantle cell lymphoma.

@en

prefLabel

Biological rational for sequen ...... tance in mantle cell lymphoma.

@en

P1433

Q38896657-6081AB1D-0D90-494B-AFCE-26DF8DD2D2AD

P1476

Q38896657-20481896-4E9C-47EF-8D02-C86043BF9EEA

P2093

Q38896657-1B37660A-3869-47A2-8CD8-785D9A2C9165

Q38896657-A5B343E4-1D70-4BD9-B608-8EFFA1419058

Q38896657-B72B3C30-DF69-45C2-BB87-9098EE8C5EF9

Q38896657-BECA3A27-A84A-4925-946A-69BC2787043C

Q38896657-C0EFC701-3128-4795-B98F-C6BA093C3F14

Q38896657-CCDD1FE4-F952-45A3-93DB-CA4DB2E51A68

Q38896657-F0146939-EF78-463C-8F4E-3B880BC81BD6

Q38896657-FF1E7219-37D4-4EE4-A6FE-2CDE95A23D87

P2860

Q38896657-09BE590A-C5B3-4EE6-8F32-E9685F27CC69

Q38896657-2397563E-A1FE-4152-87F7-145501B646FF

Q38896657-3ABE0FD7-B48F-43A6-BA41-25967A2BDB8B

Q38896657-3B0CDE31-AD0E-4E32-9AEF-7BF1A9BC91DD

Q38896657-3EBAF3F0-17CF-436B-B062-83FF362D7B20

Q38896657-4AF6EB1C-6FE6-486B-8A14-EE438B43CB54

Q38896657-504DE0FA-9530-42B0-8500-60E3FDE02405

Q38896657-58D05FFA-589D-4A26-8F61-053EED39F5BC

Q38896657-601B2491-FD23-4DEA-83F2-19EFB30B6866

Q38896657-604D7891-5471-44D1-A57A-DD99672C124A

P304

Q38896657-D538F25E-D0CA-41C7-B1E2-D4095AD22CE1

P31

Q38896657-F27AB438-FB67-42AC-9AC0-603C3CE4F5CE

P356

Q38896657-1EDA5EE2-B10A-4F4E-9CB8-22015234D272

P407

Q38896657-D68ED484-5878-48EE-AE81-25935783C7DB

P433

Q38896657-EA879D84-2008-4234-9D7B-1D4AC02996FC

P478

Q38896657-BC1229A0-991B-4F7A-BD15-435777A97048

P50

Q38896657-4E7A86B7-23C3-4465-AD17-19B9E4BA2853

P577

Q38896657-549AD97D-0A03-435E-8217-17B8670B035F

P698

Q38896657-5E1ED9B2-0514-45BC-A860-44F361F4FF66

P932

Q38896657-BF4FAF38-336F-4E70-B171-E633445ED781

P356

ONCOTARGET.3275

P1433

P1476

Biological rational for sequen ...... tance in mantle cell lymphoma.

@en

P2093

Carole Brosseau

http://www.w3.org/2001/XMLSchema#string

Catherine Pellat-Deceunynck

http://www.w3.org/2001/XMLSchema#string

Christelle Dousset

http://www.w3.org/2001/XMLSchema#string

Cyrille Touzeau

http://www.w3.org/2001/XMLSchema#string

David Chiron

http://www.w3.org/2001/XMLSchema#string

Martine Amiot

http://www.w3.org/2001/XMLSchema#string

Sophie Maïga

http://www.w3.org/2001/XMLSchema#string

Steven Le Gouill

http://www.w3.org/2001/XMLSchema#string

P2860

BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

CD40 regulates the processing of NF-kappaB2 p100 to p52

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

P304

8750-8759

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.3275

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Moreau

P577

2015-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25797245

http://www.w3.org/2001/XMLSchema#string

P932

4496181

http://www.w3.org/2001/XMLSchema#string